Enanta Pharmaceuticals Inc - Company & Market Research Reports

Enanta Pharmaceuticals is a biotechnology company that focuses on small molecule drugs for viral infections and liver diseases. Enanta’s research is currently focused on the following disease targets: Hepatitis B Virus (HBV), Non-alcoholic Steatohepatitis (NASH)/PBC and Respiratory Syncytial Virus (RSV). The company has a collaborative development and license agreement with AbbVie to develop and commercialize HCV NS3 and NS3/4A protease inhibitors. Enanta was founded in 1995 and is headquartered in Watertown, Massachusetts.


Global Hepatitis Drug Market & Clinical Trials Insight 2023 - Product Thumbnail Image

Global Hepatitis Drug Market & Clinical Trials Insight 2023

  • Report
  • 550 Pages
From
KOL Insight: Hepatitis C: the race for the first interferon-free regimen - Product Thumbnail Image

KOL Insight: Hepatitis C: the race for the first interferon-free regimen

  • Report
From
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape - Product Thumbnail Image

Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape

  • Report
  • 120 Pages
From
Non-Structural Protein 5 Inhibitor -Pipeline Insight, 2018 - Product Thumbnail Image

Non-Structural Protein 5 Inhibitor -Pipeline Insight, 2018

  • Drug Pipelines
  • 90 Pages
From
Hepatitis C: Game changing regimens to revolutionise treatment landscape - KOL Insight - Product Thumbnail Image

Hepatitis C: Game changing regimens to revolutionise treatment landscape - KOL Insight

  • Report
  • 203 Pages
From
Hepatitis C (HCV) Market Forecast & Drugs Pipeline Analysis to 2016 - Product Thumbnail Image

Hepatitis C (HCV) Market Forecast & Drugs Pipeline Analysis to 2016

  • Report
  • 72 Pages
From
Respiratory Syncytial Virus and Human Parainfluenza Virus 3 Infections Drug Development Pipeline Review, 2018 - Product Thumbnail Image

Respiratory Syncytial Virus and Human Parainfluenza Virus 3 Infections Drug Development Pipeline Review, 2018

  • Report
  • 82 Pages
From
Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2018 - Product Thumbnail Image

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2018

  • Clinical Trials
  • 277 Pages
From
Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018 - Product Thumbnail Image

Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018

  • Report
  • 159 Pages
From
2018 Primary biliary cirrhosis Drug Development- Pipeline Analysis Report - Product Thumbnail Image

2018 Primary biliary cirrhosis Drug Development- Pipeline Analysis Report

  • Report
  • 50 Pages
From
2018 Gastritis (stomach inflammation) Drug Development- Pipeline Analysis Report - Product Thumbnail Image

2018 Gastritis (stomach inflammation) Drug Development- Pipeline Analysis Report

  • Report
  • 40 Pages
From
Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2018 - Product Thumbnail Image

Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2018

  • Report
  • 241 Pages
From
Antibiotics Drugs Market: By Drug Class and By Geography - With Forecast 2016-2021 - Product Thumbnail Image

Antibiotics Drugs Market: By Drug Class and By Geography - With Forecast 2016-2021

  • Report
  • 167 Pages
From
NASH Drugs Market, 2015 - 2025 - Product Thumbnail Image

NASH Drugs Market, 2015 - 2025

  • Report
  • 188 Pages
From
Primary Biliary Cirrhosis - Pipeline Insight, 2018 - Product Thumbnail Image

Primary Biliary Cirrhosis - Pipeline Insight, 2018

  • Drug Pipelines
  • 61 Pages
From
Primary Biliary Cirrhosis - Pipeline Review, H1 2018 - Product Thumbnail Image

Primary Biliary Cirrhosis - Pipeline Review, H1 2018

  • Report
  • 111 Pages
From
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2018 - Product Thumbnail Image

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2018

  • Report
  • 237 Pages
From
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H1 2018 - Product Thumbnail Image

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H1 2018

  • Report
  • 512 Pages
From
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2017 - Product Thumbnail Image

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2017

  • Report
  • 446 Pages
From
Primary Biliary Cirrhosis - Pipeline Review, H2 2017 - Product Thumbnail Image

Primary Biliary Cirrhosis - Pipeline Review, H2 2017

  • Report
  • 106 Pages
From
Loading Indicator
adroll